IBB vs RSP
iShares Biotechnology ETF vs Invesco S&P 500 Equal Weight ETF
- • RSP has the lower expense ratio at 0.20% vs 0.44% for IBB.
- • RSP pays a higher dividend yield (1.46%).
Side-by-side metrics
| Metric | IBB | RSP |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.44% | 0.20% |
Dividend yield Trailing 12-month yield. | 0.16% | 1.46% |
AUM Assets under management — bigger funds are typically more liquid. | $11.50B | $100.66B |
YTD return | 30.22% | 16.71% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.60 | 0.80 |
P/E ratio | 25.48 | 20.31 |
Last price | $217.75 | $222.50 |
Inception | — | — |
Issuer | iShares | Invesco |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
RSP top holdings
| MRNA | Moderna Inc | 0.32% |
| PTC | PTC Inc | 0.30% |
| ACN | Accenture PLC Class A | 0.29% |
| IT | Gartner Inc | 0.26% |
| HAS | Hasbro Inc | 0.26% |
| P | Everpure Inc Class A | 0.26% |
| MTD | Mettler-Toledo International Inc | 0.25% |
| CRL | Charles River Laboratories International Inc | 0.25% |
| CCL | Carnival Corporation Ltd | 0.25% |
| RVTY | Revvity Inc | 0.25% |
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About RSP
RSP (Invesco S&P 500 Equal Weight ETF) is S&P 500 with each stock equally weighted. Managed by Invesco, the fund carries $100.7B in assets under management, an expense ratio of 0.20%, a dividend yield of 1.46%. Its largest holding is Moderna Inc (MRNA), which represents 0.3% of the portfolio. Real Estate is the fund's largest sector exposure at 5.8%.